Анальгетическая терапия и проблема коморбидности
https://doi.org/10.14412/1996-7012-2019-3-116-125
Аннотация
Анальгетическая терапия — необходимый элемент комплексного лечения больных с ревматическими заболеваниями (РЗ). Однако обезболивающие препараты способны вызывать серьезные осложнения. Этот риск особенно велик у пациентов с коморбидными заболеваниями. Поэтому индивидуальный выбор фармакологических средств для контроля острой и хронической боли у конкретного пациента во многом зависит от наличия коморбидной патологии. В настоящем обзоре рассматриваются частота коморбидных заболеваний при различных РЗ, особенности нежелательных реакций на фоне приема основных анальгетиков — парацетамола, опиоидов, нестероидных противовоспалительных препаратов (НПВП), а также вопросы рационального выбора НПВП в реальной клинической практике.
Ключевые слова
Об авторе
А. Е. Каратеев
Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
Россия
Каратеев Андрей Евгеньевич.
115522, Москва, Каширское шоссе, 34А.
Литература
1. Насонов ЕЛ, Лила АМ, Галушко ЕА, Амирджанова ВН. Стратегия развития ревматологии: от научных достижений к практическому здравоохранению. Научно-практическая ревматология. 2017; 55(4):339-43. doi: 10.14412/1995-4484-2017-339-343
2. Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. 456 с.
3. Гордеев АВ, Галушко ЕА, Насонов ЕЛ. Концепция мультиморбидности в ревматологической практике. Научно-практическая ревматология. 2014;52(4):362-5. doi: 10.14412/1995-4484-2014-362-365
4. Муравьев ЮВ, Муравьева ЛА. Дискуссионные проблемы фармакологического надзора. Научно-практическая ревматология. 2018;56(1):123-6. doi: 10.14412/1995-4484-2018-123-126
5. Муравьев ЮВ. Проблема неблагоприятных реакций на лекарственные препараты. Научно-практическая ревматология. 2010;48(3):13-4. doi: 10.14412/1995-4484-2010-437
6. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014 Jan;73(1):62-8. doi: 10.1136/annrheumdis-2013-204223. Epub 2013 Oct 4.
7. An J, Nyarko E, Hamad MA. Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis. Clin Rheumatol. 2019 May 27. doi: 10.1007/s10067-019-04613-2. [Epub ahead of print]
8. Fernandez-Carballido C, Martin-Martinez MA, Garcia-Gomez C, et al. Impact of Comorbidity on Physical Function in Patients with Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics. Results from the CARdiovascular in rheuMAtology (CARMA) study. Arthritis Care Res (Hoboken). 2019 Apr 29. doi: 10.1002/acr.23910. [Epub ahead of print]
9. Zhao SS, Radner H, Siebert S, et al. Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatology (Oxford). 2019 Apr 9. pii: kez119. doi: 10.1093/rheumatology/kez119. [Epub ahead of print]
10. Swain S, Sarmanova A, Coupland C, et al. Comorbidities in Osteoarthritis: A systematic review and meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2019 Jun 17. doi: 10.1002/acr.24008. [Epub ahead of print]
11. Calders P, Van Ginckel A. Presence of comorbidities and prognosis of clinical symptoms in knee and/or hip osteoarthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018 Jun;47(6):805-813. doi: 10.1016/j.semarthrit.2017.10.016. Epub 2017 Oct 31.
12. De Rooij M, van der Leeden M, Heymans MW, et al. Prognosis of Pain and Physical Functioning in Patients With Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2016 Apr;68(4):481-92. doi: 10.1002/acr.22693.
13. Clauw DJ, Essex MN, Pitman V, Jones KD. Reframing chronic pain as a dis-ease, not a symptom: rationale and implications for pain management. Postgrad Med. 2019 Apr;131(3):185-198. doi: 10.1080/00325481.2019.1574403. Epub 2019 Feb 11.
14. Каратеев АЕ, Попкова ТВ, Новикова ДС и др. Оценка риска желудочно-кишечных и сердечно-сосудистых осложнений, ассоциированных с приемом нестероидных противовоспалительных препаратов в популяции СНГ: предварительные данные эпидемиологического исследования КОРОНА-2. Научно-практическая ревматология. 2014;52(6):600-6. doi: 10.14412/1995-4484-2014-600-606
15. Каратеев АЕ, Алексеева ЛИ, Цурган АВ, Гонтаренко НА. Терапия острой/подострой скелетно-мышечной боли: результаты наблюдательного исследования АЛИСА (Анальгетическое Лечение с Использованием Системного Алгоритма). Терапевтический архив. 2017;(12):175-84.
16. Каратеев АЕ, Погожева ЕЮ, Филатова ЕС и др. Результаты российского многоцентрового исследования НОТА (НПВП для Обезболивания: Терапевтический Анализ). Терапевтический архив. 2018;(6):65-73.
17. Jozwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014 Jan-Feb;71(1):11-23.
18. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Apr 30. pii: S0049-0172(19)30043-5. doi: 10.1016/j.semarthrit.2019.04.008. [Epub ahead of print]
19. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007 Mar 27; 115(12):1634-42. Epub 2007 Feb 26.
20. Richette P, Latourte A, Frazier A. Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend? Expert Opin Drug Saf. 2015 Aug;14(8):1259-68. doi: 10.1517/14740338.2015.1056776. Epub 2015 Jul 1.
21. Richette P. How safe is acetaminophen in rheumatology? Joint Bone Spine. 2014 Jan; 81(1):4-5. doi: 10.1016/j.jbspin.2013.11.010. Epub 2013 Dec 31.
22. Leopoldino AO, Machado GC, Ferreira PH, et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst Rev. 2019 Feb 25;2:CD013273. doi: 10.1002/14651858.CD013273.
23. Saragiotto BT, Machado GC, Ferreira ML, et al. Paracetamol for low back pain. Cochrane Database Syst Rev. 2016 Jun 7; (6):CD012230. doi: 10.1002/14651858.CD012230.
24. De Abajo FJ, Gil MJ, Bryant V, et al. Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database. Eur J Clin Pharmacol. 2013 Mar;69(3):691-701. doi: 10.1007/s00228-012-1386-3. Epub 2012 Sep 6.
25. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001 Sep;12(5):570-6.
26. McIntosh JH, Fung CS, Berry G, Piper DW. Smoking, nonsteroidal anti-inflammatory drugs, and acetaminophen in gastric ulcer. A study of associations and of the effects of previous diagnosis on exposure patterns. Am JEpidemiol. 1988 Oct;128(4): 761-70.
27. McCrae JC, Morrison EE, MacIntyre IM, et al. Long-term adverse effects of paracetamol — a review. Br J Clin Pharmacol. 2018 Oct;84(10):2218-2230. doi: 10.1111/bcp.13656. Epub 2018 Jul 20.
28. Roberto G, Simonetti M, Piccinni C, et al. Risk of Acute Cerebrovascular and Cardiovascular Events Among Users of Acetaminophen or an Acetaminophen-Codeine Combination in a Cohort of Patients with Osteoarthritis: A Nested Case-Control Study. Pharmacotherapy. 2015 Oct;35(10): 899-909. doi: 10.1002/phar.1646.
29. Pontes C, Marsal JR, Elorza JM, et al. Analgesic Use and Risk for Acute Coronary Events in Patients With Osteoarthritis: A Population-based, Nested Case-control Study. Clin Ther. 2018 Feb;40(2):270-283. doi: 10.1016/j.clinthera.2017.12.011. Epub 2018 Feb 3.
30. Girard P, Sourdet S, Cantet C, et al. Acetaminophen Safety: Risk of Mortality and Cardiovascular Events in Nursing Home Residents, a Prospective Study. J Am Geriatr Soc. 2019 Jun;67(6):1240-1247. doi: 10.1111/jgs.15861. Epub 2019 Mar 26.
31. Chung YT, Chou CY, Tsai WC, et al. Acetaminophen Poisoning May Increase Coronary Artery Disease Risk: A Nationwide Cohort Study. Cardiovasc Toxicol. 2018 Aug; 18(4):386-391. doi: 10.1007/s12012-017-9442-y.
32. Stollings JL, Wheeler AP, Rice TW. Incidence and characterization of acute kid-ney injury after acetaminophen overdose. J Crit Care. 2016 Oct;35:191-4. doi: 10.1016/j.jcrc.2016.06.004. Epub 2016 Jun 21.
33. Chen YG, Lin CL, Dai MS, et al. Risk of Acute Kidney Injury and Long-Term Outcome in Patients With Acetaminophen Intoxication: A Nationwide Population-Based Retrospective Cohort Study. Medicine (Baltimore). 2015 Nov;94(46):e2040. doi: 10.1097/MD.0000000000002040.
34. Graham GG, Graham RI, Day RO. Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). Curr Pharm Des. 2002;8(12):1063-75.
35. Hiragi S, Yamada H, Tsukamoto T, et al. Acetaminophen administration and the risk of acute kidney injury: a self-controlled case series study. Clin Epidemiol. 2018 Mar 6;10: 265-276. doi: 10.2147/CLEP.S158110. eCollection 2018.
36. Montrief T, Koyfman A, Long B. Acute liver failure: A review for emergency physicians. Am JEmergMed. 2019 Feb;37(2):329-337. doi: 10.1016/j.ajem.2018.10.032. Epub 2018 Oct 22.
37. Bunchorntavakul C, Reddy KR. Acetaminophen (APAP or N-Acetyl-p-Aminophenol) and Acute Liver Failure. Clin Liver Dis. 2018 May;22(2):325-346. doi: 10.1016/j.cld.2018.01.007. Epub 2018 Feb 9.
38. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology. 1995 Sep;22(3):767-73.
39. Prescott LF. Paracetamol, alcohol and the liver. Br JClin Pharmacol. 2000 Apr;49(4): 291-301.
40. Kuffner EK, Dart RC, Bogdan GM, et al. Effect of maximal daily doses of acetaminophenon the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med. 2001 Oct 8;161(18): 2247-52.
41. Dart RC, Green JL, Kuffner EK, et al. The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol - a randomized study. Aliment Pharmacol Ther. 2010 Aug;32(3):478-86. doi: 10.1111/j.1365-2036.2010.04364.x. Epub 2010 May 20.
42. Andreu V, Gomez-Angelats E, Bruguera M, Rodes J. Severe hepatitis from therapeutic doses of paracetamol in an alcoholic patient. Gastroenterol Hepatol. 1999 May;22(5):235-7.
43. Mofredj A, Cadranel JF, Darchy B, et al. Hepatotoxicity caused by therapeutic doses of paracetamol in alcoholics. Report of 2 cases of fatal hepatitis in cirrhosis. Ann Med Interne (Paris). 1999 Oct;150(6):507-11.
44. Hyvernat H, Vandenbos F, Anty R, et al. Fulminant hepatitis after a therapeutic dose of acetaminophen in a chronic alcoholic patient. Rev Med Interne. 2004 Mar;25(3): 251-2.
45. Jamison RN, Mao J. Opioid Analgesics. Mayo Clin Proc. 2015 Jul;90(7):957-68. doi: 10.1016/j.mayocp.2015.04.010.
46. Rawal H, Patel BM. Opioids in Cardiovascular Disease: Therapeutic Options. J Cardiovasc Pharmacol Ther. 2018 Jul;23(4): 279-291. doi: 10.1177/1074248418757009. Epub 2018 Mar 11.
47. Biondi DM, Xiang J, Etropolski M, Moskovitz B. Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis. Clin DrugInvestig. 2014 Aug;34(8):565-76. doi: 10.1007/s40261-014-0209-y.
48. Channell JS, Schug S. Toxicity of tapentadol: a systematic review. Pain Manag. 2018 Sep 1;8(5):327-339. doi: 10.2217/pmt-2018-0027. Epub 2018 Aug 6.
49. Lanas A, Serrano P, Bajador E, et al. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol. 2003 Feb; 15(2):173-8.
50. https://www.rlsnet.ru/mnn_index_id_6578.htm#protivopokazaniya
51. https://www.rlsnet.ru/mnn_index_id_1288.htm#protivopokazaniya
52. Radner H, Ramiro S, Buchbinder R, et al. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. Cochrane Database Syst Rev. 2012 Jan 18;1:CD008951. doi: 10.1002/14651858.CD008951.pub2.
53. Marks JL, van der Heijde DM, Colebatch AN, et al. Pain pharmacotherapy in patients with inflammatory arthritis and concurrent cardiovascular or renal disease: a Cochrane systematic review. J Rheumatol Suppl. 2012 Sep;90:81-4. doi: 10.3899/jrheum.120347.
54. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010 Dec 13;170(22):1968-76. doi: 10.1001/archinternmed.2010.391.
55. Zeng C, Dubreuil M, LaRochelle MR, et al. Association of Tramadol With All-Cause Mortality Among Patients With Osteoarthritis. JAMA. 2019 Mar 12;321(10):969-982. doi: 10.1001/jama.2019.1347.
56. Schwan J, Sclafani J, Tawfik. Chronic Pain Management in the Elderly. Anesthesiol Clin. 2019 Sep;37(3):547-560. doi: 10.1016/j.anclin.2019.04.012. Epub 2019 Jun 18.
57. Behzadi M, Joukar S, Beik A. Opioids and Cardiac Arrhythmia: A Literature Review. MedPrinc Pract. 2018;27(5):401-414. doi: 10.1159/000492616. Epub 2018 Aug 2.
58. Bruun SB, Petersen I, Kristensen NR, et al. Selective serotonin reuptake inhibitor use and mortality, postoperative complications, and quality of care in hip fracture patients: a Danish nationwide cohort study. Clin Epidemiol. 2018 Aug 27;10:1053-1071. doi: 10.2147/CLEP.S166309. eCollection 2018.
59. Seppala LJ, van de Glind EMM, Daams JG, et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-analysis: III. Others. J Am Med Dir Assoc. 2018 Apr;19(4): 372.e1-372.e8. doi: 10.1016/j.jamda.2017.12.099. Epub 2018 Mar 2.
60. Kvasnovsky CL, Papagrigoriadis S, Bjarnason I. Increased diverticular complications with nonsteriodal antiinflammatory drugs and other medications: a systematic review and meta-analysis. Colorectal Dis. 2014 Jun;16(6):O189-96. doi: 10.1111/codi.12516.
61. Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019 Apr;36(Suppl 1):15-24. doi: 10.1007/s40266-019-00660-1.
62. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18;368(9549):1771-81.
63. Laine L, Curtis SP, Cryer B, et al; MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007 Feb 10; 369(9560):465-73.
64. Krum H, Curtis SP, Kaur A, et al. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur J Heart Fail. 2009 Jun;11(6):542-50. doi: 10.1093/eurjhf/hfp054. Epub 2009 Apr 19.
65. Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010 Jul 17;376(9736):173-9. doi: 10.1016/S0140-6736(10)60673-3. Epub 2010 Jun 16.
66. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13.
67. Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56(Прил. 1):1-29. doi: 10.14412/1995-4484-2018-1-29
68. Harirforoosh S, Jamali F. Renal adverse effects of non-steroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009 Nov;8(6): 669-81. doi: 10.1517/14740330903311023
69. Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal antiinflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017 Aug 1;18(1):256. doi: 10.1186/s12882-017-0673-8
70. Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005 Mar;45(3):531-9. doi: 10.1053/j.ajkd.2004.12.005
71. Lipworth L, Abdel-Kader K, Morse J, et al. High prevalence of non-steroidal anti-inflammatory drug use among acute kidney injury survivors in the southern community cohort study. BMC Nephrol. 2016 Nov 24; 17(1):189. doi: 10.1186/s12882-016-0411-7
72. Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal AntiInflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015 Sep;66(3): 524-33. doi: 10.1161/HYPERTENSIONA-HA.114.05105. Epub 2015 Jul 13.
73. Mu ller B, Pruijm M, Adler S, et al. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis. 2015 Apr;74(4):718-23. doi: 10.1136/annrheumdis-2013-204078. Epub 2013 Dec 19.
74. Nderitu P, Doos L, Jones PW, et al. Nonsteroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013 Jun;30(3):247-55. doi: 10.1093/fampra/cms086. Epub 2013 Jan 8.
75. Иголкина ЕВ, Чичасова НВ, Имаметдинова ГР. Ацеклофенак в лечении патологии опорно-двигательного аппарата. Современная ревматология. 2017;11(3): 99-105. doi: 10.14412/1996-7012-2017-3-99-105
76. Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78. doi: 10.2165/00003495-200161090-00012
77. Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-18. doi: 10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.
78. Каратеев АЕ, Цурган АВ. Ацеклофенак: опыт российских исследований. Современная ревматология. 2017;11(4):89—94. doi: 10.14412/1996-7012-2017-4-89-94
Рецензия
Для цитирования:
Каратеев АЕ. Анальгетическая терапия и проблема коморбидности. Современная ревматология. 2019;13(3):116-125. https://doi.org/10.14412/1996-7012-2019-3-116-125
For citation:
Karateev AE. Analgesic therapy and a problem of comorbidity. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(3):116-125. (In Russ.) https://doi.org/10.14412/1996-7012-2019-3-116-125
Просмотров:
1125
Послать статью по эл. почте 